Sotera Health Company (SHC) Key Metrics
SHC valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $5.11B
- Enterprise value
- $7.13B
- P/E (TTM)
- 31.4 10-yr median 76.3
- Forward P/E
- 17.8
- PEG ratio
- 1.68
- Price / sales
- 4.2 10-yr median 4.4
- Price / book
- 7.8 10-yr median 10.2
- EV / EBITDA
- 13.4 10-yr median 16.7
- Dividend yield
- —
- Beta
- 1.85
SHC key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSHC valuation Price multiples at each fiscal year-end price.
SHC returns How much profit the business earns on the capital it uses.
SHC per-share figures Results divided by the shares outstanding at year-end.
SHC financial health Debt, liquidity and how easily interest is covered.
SHC efficiency & capital use Working capital cycle and where the cash goes.
SHC valuation history
SHC returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SHC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SHC cash returned to shareholders
SHC price vs earnings per share
SHC key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $5.05B | $3.90B | $4.77B | $2.33B | $6.58B | $7.77B | — | — |
| Enterprise value | $6.98B | $5.97B | $6.80B | $3.97B | $8.30B | $9.58B | — | — |
| P/E ratio | 64.8 | 87.8 | 92.9 | — | 56.3 | — | — | — |
| Price / sales | 4.3 | 3.5 | 4.5 | 2.3 | 7.1 | 9.5 | — | — |
| Price / book | 8.3 | 9.6 | 10.8 | 6.7 | 11.2 | 17.2 | — | — |
| Price / free cash flow | 33.9 | 86.4 | — | 24.4 | 36.7 | 115.9 | — | — |
| Price / operating cash flow | 17.6 | 17.4 | — | 8.4 | 23.4 | 64.5 | — | — |
| EV / sales | 6.0 | 5.4 | 6.5 | 4.0 | 8.9 | 11.7 | — | — |
| EV / EBITDA | 15.8 | 13.5 | 16.7 | — | 20.7 | 29.9 | — | — |
| EV / free cash flow | 46.8 | 132.4 | — | 41.5 | 46.3 | 142.8 | — | — |
| Earnings yield | 1.5% | 1.1% | 1.1% | −10.0% | 1.8% | −0.5% | — | — |
| Free cash flow yield | 3.0% | 1.2% | −7.6% | 4.1% | 2.7% | 0.9% | — | — |
| Dividend yield | — | — | — | — | 0.0% | 1.9% | — | — |
| Shareholder yield (dividends + buybacks) | — | 0.1% | 0.1% | 0.0% | 0.0% | 2.4% | — | — |
| Share price at fiscal year-end | $17.64 | $13.68 | $16.85 | $8.33 | $23.55 | $27.44 | — | — |
| Per share | ||||||||
| Revenue per share | $4.06 | $3.86 | $3.70 | $3.58 | $3.33 | $2.89 | $2.74 | $3.03 |
| Earnings per share | $0.27 | $0.16 | $0.18 | −$0.83 | $0.42 | −$0.14 | −$0.07 | −$0.02 |
| Operating cash flow per share | $1.00 | $0.79 | −$0.52 | $0.99 | $1.01 | $0.43 | $0.52 | $0.49 |
| Free cash flow per share | $0.52 | $0.16 | −$1.28 | $0.34 | $0.64 | $0.24 | $0.32 | $0.19 |
| Cash per share | $1.21 | $0.97 | $1.05 | $1.41 | $0.38 | $0.36 | $0.22 | $0.39 |
| Book value per share | $2.12 | $1.42 | $1.57 | $1.25 | $2.10 | $1.60 | −$2.26 | $0.18 |
| Tangible book value per share | −$2.74 | −$3.49 | −$3.83 | −$4.44 | −$4.06 | −$4.61 | −$8.35 | −$7.09 |
| Dividends per share | — | — | — | — | $0.00 | $0.53 | $2.43 | $0.71 |
| Capex per share | $0.48 | $0.63 | $0.76 | $0.65 | $0.37 | $0.19 | $0.20 | $0.29 |
| Debt per share | $7.94 | $8.25 | $8.22 | $7.25 | $6.54 | $6.74 | $10.01 | $9.09 |
| Shares outstanding | 286.4M | 284.9M | 283.2M | 280.1M | 279.4M | 283.2M | 284.4M | 246.2M |
| Change in shares outstanding | +0.5% | +0.6% | +1.1% | +0.3% | −1.4% | −0.4% | +15.5% | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | 15.4% | 10.5% | 12.9% | −49.9% | 22.5% | — | — | −13.2% |
| Return on invested capital (ROIC) | 8.3% | 6.0% | 6.2% | 9.1% | 7.5% | 7.4% | 6.7% | 1.8% |
| Return on assets (ROA) | 2.5% | 1.4% | 1.6% | −7.9% | 4.2% | −1.4% | −0.8% | −0.2% |
| Return on tangible assets | 4.2% | 2.7% | 3.2% | −15.3% | 10.9% | −3.9% | −2.5% | −0.6% |
| Free cash flow margin | 12.8% | 4.1% | −34.6% | 9.5% | 19.3% | 8.2% | 11.8% | 6.3% |
| Income quality (OCF / net income) | 3.68 | 5.05 | −2.88 | — | 2.41 | — | — | — |
| Financial health | ||||||||
| Total debt | $2.27B | $2.35B | $2.33B | $2.03B | $1.83B | $1.91B | $2.85B | $2.24B |
| Cash & short-term investments | $346.5M | $277.2M | $296.4M | $395.2M | $106.9M | $102.4M | $62.9M | $96.3M |
| Net debt | $1.93B | $2.07B | $2.03B | $1.64B | $1.72B | $1.81B | $2.79B | $2.14B |
| Debt / equity | 3.75 | 5.81 | 5.24 | 5.80 | 3.12 | 4.22 | — | 50.45 |
| Debt / assets | 0.70 | 0.77 | 0.74 | 0.65 | 0.66 | 0.69 | 1.10 | 0.83 |
| Net debt / EBITDA | 4.36 | 4.69 | 4.99 | — | 4.29 | 5.65 | 9.18 | 6.81 |
| Current ratio | 2.46 | 2.75 | 2.42 | 0.81 | 2.15 | 2.24 | 2.04 | 2.18 |
| Quick ratio | 2.22 | 2.50 | 2.21 | 0.77 | 1.81 | 2.00 | 1.73 | 1.92 |
| Interest coverage | 2.5 | 1.8 | 1.9 | 3.1 | 3.5 | 1.0 | 1.2 | 0.6 |
| Working capital | $363.8M | $335.0M | $326.6M | −$146.6M | $184.8M | $174.4M | $128.4M | $169.5M |
| Invested capital | $2.53B | $2.48B | $2.47B | $1.99B | $2.31B | $2.26B | $2.14B | $2.19B |
| Tangible asset value | −$785.4M | −$993.8M | −$1.08B | −$1.24B | −$1.13B | −$1.30B | −$2.37B | −$1.74B |
| Net current asset value | −$2.04B | −$2.14B | −$2.13B | −$2.12B | −$1.86B | −$1.99B | −$2.97B | −$2.35B |
| Graham number | $3.60 | $2.23 | $2.53 | — | $4.44 | — | — | — |
| Graham net-net per share | −$7.50 | −$7.86 | −$7.89 | −$7.99 | −$7.05 | −$7.37 | −$10.75 | −$9.92 |
| Capital allocation | ||||||||
| Dividends paid | — | — | — | — | $0 | $150.0M | $691.2M | $175.8M |
| Share buybacks (net) | — | $4.4M | $4.1M | $393,000 | $1.4M | $34.0M | — | — |
| Dividend payout ratio | — | — | — | — | 0.0% | — | — | — |
| Dividends + buybacks / free cash flow | — | 9.8% | — | 0.4% | 0.8% | 274.3% | 753.0% | 374.5% |
| Capex / revenue | 11.9% | 16.3% | 20.5% | 18.2% | 11.0% | 6.5% | 7.4% | 9.7% |
| Capex / operating cash flow | 48.1% | 79.9% | — | 65.6% | 36.3% | 44.4% | 38.4% | 60.7% |
| Capex / depreciation | 0.99 | 1.09 | 1.36 | 1.25 | 0.68 | 0.37 | 0.39 | 0.49 |
| Stock-based compensation / revenue | 2.7% | 3.3% | 3.1% | 2.1% | 1.5% | 1.3% | 0.9% | 0.9% |
| SG&A / revenue | 21.7% | 22.0% | 23.1% | 24.5% | 21.3% | 21.8% | 18.9% | 17.9% |
| Efficiency | ||||||||
| Days sales outstanding | 53.7 | 56.6 | 57.6 | 52.7 | 51.9 | 54.1 | 59.4 | 69.3 |
| Days of inventory on hand | 38.2 | 35.7 | 33.0 | 37.4 | 39.1 | 34.8 | 35.7 | 35.3 |
| Days payables outstanding | 46.9 | 46.2 | 56.1 | 60.1 | 55.4 | 46.0 | 42.1 | 43.5 |
| Cash conversion cycle (days) | 45.0 | 46.1 | 34.5 | 30.0 | 35.6 | 43.0 | 53.0 | 61.1 |
| Receivables turnover | 6.80 | 6.45 | 6.34 | 6.93 | 7.03 | 6.74 | 6.15 | 5.27 |
| Payables turnover | 7.79 | 7.90 | 6.50 | 6.08 | 6.59 | 7.94 | 8.67 | 8.39 |
| Inventory turnover | 9.55 | 10.22 | 11.05 | 9.77 | 9.34 | 10.48 | 10.21 | 10.34 |
| Asset turnover | 0.37 | 0.35 | 0.34 | 0.34 | 0.34 | 0.31 | 0.29 | 0.28 |
| Average receivables | $171.0M | $170.7M | $165.6M | $144.9M | $132.5M | $121.3M | $126.6M | $141.6M |
| Average payables | $66.5M | $63.1M | $72.6M | $73.5M | $62.6M | $47.2M | $44.2M | $46.4M |
| Average inventory | $54.3M | $48.7M | $42.7M | $45.7M | $44.2M | $35.7M | $37.5M | $37.6M |
| Intangibles / total assets | 42.6% | 45.5% | 48.8% | 51.1% | 61.6% | 63.7% | 67.1% | 66.1% |
Computed from SHC's annual financial statements (latest annual report filed February 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SHC valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Sotera Health traded at 64.8 times earnings, against a 8-year median of 76.3. Based on the latest twelve months, the trailing P/E is 31.4 and the forward P/E is 17.8. Sotera Health earned a return on equity of 15.4% and a return on invested capital of 8.3% in fiscal 2025. It ended the year with $2.3 billion of debt and $346.5 million in cash and short-term investments, net debt of $1.9 billion. The share count rose 16.4% from 246.2M to 286.4M over 7 years.
See the SHC income statement, the SHC chart for price history, or the SHC stock overview for the latest quote and news.
SHC key metrics FAQ
What is Sotera Health's P/E ratio?
Sotera Health's trailing P/E ratio is 31.4 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 17.8. At the end of fiscal 2025 it was 64.8, compared with a 8-year median of 76.3.
What is Sotera Health's EV/EBITDA?
Sotera Health's enterprise value was 15.8 times EBITDA at the end of fiscal 2025 (enterprise value $7.0 billion, EBITDA $442.3 million); the current EV/EBITDA is 13.4.
What is Sotera Health's return on equity?
Sotera Health's return on equity (ROE) was 15.4% in fiscal 2025: net income of $77.9 million on average shareholders' equity of $505.5 million.
What is Sotera Health's ROIC?
Sotera Health's return on invested capital was 8.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Sotera Health have?
Sotera Health had total debt of $2.3 billion at the end of fiscal 2025, a debt-to-equity ratio of 3.75 and $1.9 billion of net debt (4.36 times EBITDA).
What is Sotera Health's free cash flow yield?
Sotera Health generated $149.2 million of free cash flow in fiscal 2025, a free cash flow yield of 3.0% on its market value at year-end ($5.1 billion).
What is Sotera Health's current ratio?
Sotera Health's current ratio was 2.46 at the end of fiscal 2025: current assets were 2.46 times current liabilities.